To the full analysis
TransMedics Group stock: growth
TMDXTransMedics Group reported $605.49M in revenue for fiscal 2025, up 37.1% on the prior year, up 88.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
66.3%
per year from 2016 to 2025, per share 51.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2016 | |
|---|---|---|
| Revenue | 88.2% | 66.3% |
| Revenue per share | 76.6% | 51.3% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2016 | $6.21M | −$24.07M | −$25.59M |
| 2017 | $7.69M | −$20.82M | −$23.36M |
| 2018 | $13.02M | −$23.76M | −$26.4M |
| 2019 | $23.6M | −$33.55M | −$32.45M |
| 2020 | $25.64M | −$28.75M | −$30.72M |
| 2021 | $30.26M | −$44.22M | −$32.38M |
| 2022 | $93.46M | −$36.23M | −$57.72M |
| 2023 | $241.62M | −$25.03M | −$192.09M |
| 2024 | $441.54M | $35.46M | −$80.94M |
| 2025 | $605.49M | $190.29M | $133.59M |
Revenue by segment
How TransMedics Group, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Product62%
- Service Revenue38%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Product | $79.23M | $176.05M | $273.87M | $372.4M | 61.5% |
| Service Revenue | $14.23M | $65.55M | $167.67M | $233.09M | 38.5% |
| Total revenue | $93.46M | $241.62M | $441.54M | $605.49M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 23 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.